Healthy and functional cells from discovery
to manufacturing

We enable transformative therapies with our patent-pending continuous Flowfect™ cell engineering platforms. The non-viral Flowfect™ technology is a fast, scalable, and gentle process that yields billions of high-quality engineered cells in minutes while maintaining cell health and function.

learn more

Flowfect™ Tx Revealed

The future in non-viral delivery for
cell therapy manufacturing

KYTOPEN enables cell engineering from discovery to manufacturing

Technology

We are transforming cell engineering

The Flowfect™ technology combines continuous fluid flow with electric fields for high efficiency delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells. By carefully synchronizing the pulse delivery with the fluid flow we have eliminated the harmful effects of traditional transfection via static electroporation. Our ex vivo cell engineering platform is compatible with primary cells being developed for immuno-oncology and gene editing applications.

PRESERVED VIABILITY & FUNCTIONALITY

Our platform allows you to safely engineer your cells with minimal impact to their overall health and function. High-quality engineered cell products upfront will ultimate translate into faster cell therapy access for patients.

Kytopen

SCALABLE CELL ENGINEERING

The Flowfect™ platform combines proprietary electric fields and continuous fluid flow to engineer cells. We currently process billions of cells in minutes which makes our technology amenable to autologous and allogenic cell therapy applications. Our goal is to enable efficient and cost-effective manufacturing of cell therapies in days versus weeks.

AUTOMATED
HIGH THROUGHPUT
DISCOVERY

We have fully automated cell engineering at the discovery scale. Whether you’re optimizing transfection conditions or discovering the next-generation cell therapy, Flowfect™ will accelerate your time to market.

KYTOPEN empowers your cells to flow from theory to therapy

Team

Meet the team

PAULO A. GARCIA, PH.D.
CEO & Co-Founder

Dr. Paulo A. Garcia co-invented the Flowfect™ technology while he was a Research Scientist at MIT. He is currently leading the development and commercialization efforts of the proprietary cell engineering platform for therapeutic and biotechnology applications.

CULLEN R. BUIE, PH.D.
Co-Founder

Cullen R. Buie, Ph.D. is a Tenured Professor of Mechanical Engineering at MIT and co-inventor of the high-throughput genetic modification technology. He brings expertise in the areas of microfluidics, microfabrication, and experimental fluid mechanics to Kytopen.

BETHANY GRANT, M.S.
Head of Research &
Development

Bethany has focused her career on bringing innovative medical device solutions to market. She led concepts through launch and acquisition, and directed innovation and product development at J&J. She graduated from MIT with a B.S. and M.S. in Aeronautical and Astronautical Engineering.

RAMEECH MCCORMACK, M.S.
R&D Engineer

Rameech McCormack, M.S. master’s graduate from the Mechanical Engineering Department at MIT. He is also a co-inventor of the high throughput Flowfect™ technology. Rameech leads the effort in product manufacturing, design, and integration.

ROSS BEIGHLEY, B.S.
Senior Systems Engineer

Ross Beighley, B.S. graduated from Tufts University where he studied Computer Engineering and Biomedical Engineering. His professional experience centers on transitioning benchtop solutions to worldwide markets through automation.

JESSICA M. SIDO, PH.D.
Scientific Liaison

Jessica M. Sido, Ph.D. graduated from the University of South Carolina School of Medicine where she worked on T cell driven inflammatory responses. She recently completed her postdoctoral research in cancer immunology at Harvard Medical School and Dana-Farber Cancer Institute.

JAMES HEMPHILL, PH.D.
Principal Scientist

James Hemphill, Ph.D. is a genetic engineer focused on building new functionality into human cells for therapeutic application. He received his Ph.D. in chemical biology from the University of Pittsburgh and has experience in platform development for adoptive cell therapy.

KYTOPEN enables safer and faster therapeutic development

Publications

The intersection of innovation and opportunity

Kytopen is an MIT spinout with multiple publications in high-impact scientific journals.

ASGCT2020

Flowfect™: A scalable
non-viral
delivery process for T cell engineering

DOWNLOAD PDF

ISSCR2020

Flowfect™ Transfection
of iPSCs
Maintains Cell
Pluripotency

DOWNLOAD PDF

NATURE
SCIENTIFIC REPORTS

Microfluidic screening
of electric fields for
electroporation

DOWNLOAD PDF

LAB ON A CHIP

High efficiency
hydrodynamic bacterial electrotransformation

DOWNLOAD PDF

ENVIRONMENTAL
MICROBIOLOGY

Towars establishing
model organisms for
marine protists

DOWNLOAD PDF

KYTOPEN  helps you discover efficiently

Jobs & Contact

Be part of a dynamic and growing team working at the intersection of engineering, biology, and advanced manufacturing. We have several open positions  and looking forward to receiving your CV/resume at jobs@kytopen.com if you are interested in joining us.

Sr. Research Scientist
GET IN TOUCH





captcha

With Generous Support From